Bank of Nova Scotia Cuts Stock Holdings in Cencora, Inc. $COR

Bank of Nova Scotia lowered its stake in shares of Cencora, Inc. (NYSE:COR) by 83.7% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 25,795 shares of the company’s stock after selling 132,121 shares during the quarter. Bank of Nova Scotia’s holdings in Cencora were worth $7,735,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of the stock. Atlantic Edge Private Wealth Management LLC grew its stake in shares of Cencora by 70.0% in the 2nd quarter. Atlantic Edge Private Wealth Management LLC now owns 85 shares of the company’s stock worth $25,000 after acquiring an additional 35 shares in the last quarter. Vermillion & White Wealth Management Group LLC lifted its position in shares of Cencora by 69.4% during the second quarter. Vermillion & White Wealth Management Group LLC now owns 105 shares of the company’s stock valued at $31,000 after purchasing an additional 43 shares in the last quarter. Twin Peaks Wealth Advisors LLC purchased a new position in Cencora during the second quarter worth about $52,000. Caitong International Asset Management Co. Ltd bought a new stake in Cencora in the 2nd quarter worth about $61,000. Finally, ANTIPODES PARTNERS Ltd purchased a new stake in Cencora in the 2nd quarter valued at about $61,000. 97.52% of the stock is currently owned by institutional investors.

Insider Activity at Cencora

In related news, Chairman Steven H. Collis sold 31,350 shares of Cencora stock in a transaction that occurred on Tuesday, September 16th. The shares were sold at an average price of $289.86, for a total value of $9,087,111.00. Following the completion of the transaction, the chairman directly owned 305,913 shares in the company, valued at approximately $88,671,942.18. The trade was a 9.30% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Robert P. Mauch sold 5,097 shares of the business’s stock in a transaction on Monday, October 20th. The shares were sold at an average price of $326.80, for a total transaction of $1,665,699.60. Following the sale, the chief executive officer directly owned 37,940 shares in the company, valued at $12,398,792. The trade was a 11.84% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 46,640 shares of company stock valued at $14,099,338. 10.80% of the stock is owned by insiders.

Cencora Stock Up 1.0%

COR stock opened at $340.63 on Thursday. The stock has a fifty day moving average of $341.71 and a 200-day moving average of $310.60. Cencora, Inc. has a fifty-two week low of $223.92 and a fifty-two week high of $377.54. The company has a market capitalization of $66.08 billion, a price-to-earnings ratio of 42.85, a PEG ratio of 1.60 and a beta of 0.63. The company has a debt-to-equity ratio of 4.32, a quick ratio of 0.55 and a current ratio of 0.90.

Cencora (NYSE:COR) last released its quarterly earnings data on Wednesday, November 5th. The company reported $3.84 EPS for the quarter, beating the consensus estimate of $3.79 by $0.05. The business had revenue of $83.73 billion for the quarter, compared to the consensus estimate of $83.36 billion. Cencora had a net margin of 0.48% and a return on equity of 227.15%. The company’s revenue was up 5.9% compared to the same quarter last year. During the same period in the prior year, the firm earned $3.34 earnings per share. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. As a group, equities research analysts predict that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, December 1st. Investors of record on Friday, November 14th were paid a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date was Friday, November 14th. This is an increase from Cencora’s previous quarterly dividend of $0.55. Cencora’s dividend payout ratio is currently 30.19%.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on COR shares. Wall Street Zen downgraded Cencora from a “buy” rating to a “hold” rating in a research note on Friday, November 28th. Weiss Ratings reissued a “hold (c+)” rating on shares of Cencora in a research report on Monday. JPMorgan Chase & Co. upped their price objective on Cencora from $344.00 to $417.00 and gave the company an “overweight” rating in a research note on Tuesday, November 11th. TD Cowen lifted their target price on Cencora from $350.00 to $400.00 and gave the stock a “buy” rating in a research note on Monday, November 10th. Finally, Robert W. Baird boosted their price target on shares of Cencora from $355.00 to $395.00 and gave the stock an “outperform” rating in a report on Thursday, November 6th. Nine investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat, Cencora currently has a consensus rating of “Moderate Buy” and an average price target of $373.50.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.